FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1574906247> ?p ?o ?g. }

• W1574906247 abstract "Background Rebleeding is an important cause of death and disability in people with aneurysmal subarachnoid haemorrhage. Rebleeding is probably related to dissolution of the blood clot at the site of aneurysm rupture by natural fibrinolytic activity. This review is an update of a previously published Cochrane review. Objectives To assess the effects of antifibrinolytic treatment in people with aneurysmal subarachnoid haemorrhage. Search methods We searched the Cochrane Stroke Group Trials Register (February 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 1), MEDLINE (1948 to December 2012), and EMBASE (1947 to December 2012). In an effort to identify further published, unpublished, and ongoing studies we searched reference lists and trial registers, performed forward tracking of relevant references and contacted drug companies. Selection criteria Randomised trials comparing oral or intravenous antifibrinolytic drugs (tranexamic acid, epsilon amino‐caproic acid, or an equivalent) with control in people with subarachnoid haemorrhage of suspected or proven aneurysmal cause. Data collection and analysis Two review authors independently selected trials for inclusion and extracted the data. Three review authors assessed trial quality. For the primary outcome we converted the outcome scales between good and poor outcome for the analysis. We scored death from any cause and rates of rebleeding, cerebral ischaemia, and hydrocephalus per treatment group. We expressed effects as risk ratios (RR) with 95% confidence intervals (CI). We used random‐effects models for all analyses. Main results We included 10 trials involving 1904 participants. The risk of bias was low in six studies. Four studies were open label and were rated as high risk of performance bias. One of these studies was also rated as high risk for attrition bias. Four trials reported on poor outcome (death, vegetative state, or severe disability) with a pooled risk ratio (RR) of 1.02 (95% confidence interval (CI) 0.91 to 1.15). All trials reported on death from all causes with a pooled RR of 1.00 (95% CI 0.85 to 1.18). In a trial that combined short‐term antifibrinolytic treatment (< 72 hours) with preventative measures for cerebral ischaemia the RR for poor outcome was 0.85 (95% CI 0.64 to 1.14). Antifibrinolytic treatment reduced the risk of re‐bleeding reported at the end of follow‐up (RR 0.65, 95% CI 0.44 to 0.97; 78 per 1000 participants), but there was heterogeneity (I² = 62%) between the trials. The pooled RR for reported cerebral ischaemia was 1.41 (95% CI 1.04 to 1.91, 83 per 1000 participants), again with heterogeneity between the trials (I² = 52%). Antifibrinolytic treatment showed no effect on the reported rate of hydrocephalus in five trials (RR 1.11, 95% CI 0.90 to 1.36). Authors' conclusions The current evidence does not support the use of antifibrinolytic drugs in the treatment of people with aneurysmal subarachnoid haemorrhage, even in those who have concomitant treatment strategies to prevent cerebral ischaemia. Results on short‐term treatment are promising, but not conclusive. Further randomised trials evaluating short‐term antifibrinolytic treatment are needed to evaluate its effectiveness." @default.
• W1574906247 created "2016-06-24" @default.
• W1574906247 creator A5019984978 @default.
• W1574906247 creator A5023457875 @default.
• W1574906247 creator A5052591309 @default.
• W1574906247 creator A5057096729 @default.
• W1574906247 creator A5066554954 @default.
• W1574906247 creator A5077611966 @default.
• W1574906247 creator A5081542140 @default.
• W1574906247 date "2013-08-30" @default.
• W1574906247 modified "2023-10-03" @default.
• W1574906247 title "Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage" @default.
• W1574906247 cites W1574906247 @default.
• W1574906247 cites W1596296816 @default.
• W1574906247 cites W1841248562 @default.
• W1574906247 cites W1965027752 @default.
• W1574906247 cites W1973674165 @default.
• W1574906247 cites W1975255735 @default.
• W1574906247 cites W1976618106 @default.
• W1574906247 cites W1987223049 @default.
• W1574906247 cites W1989084825 @default.
• W1574906247 cites W1990316520 @default.
• W1574906247 cites W1990455434 @default.
• W1574906247 cites W1990840141 @default.
• W1574906247 cites W2000661249 @default.
• W1574906247 cites W2002097603 @default.
• W1574906247 cites W2003773432 @default.
• W1574906247 cites W2008880108 @default.
• W1574906247 cites W2015090437 @default.
• W1574906247 cites W2015601675 @default.
• W1574906247 cites W2017654105 @default.
• W1574906247 cites W2029737870 @default.
• W1574906247 cites W2032398181 @default.
• W1574906247 cites W2036810890 @default.
• W1574906247 cites W2038807608 @default.
• W1574906247 cites W2043499087 @default.
• W1574906247 cites W2049622249 @default.
• W1574906247 cites W2053827737 @default.
• W1574906247 cites W2054138225 @default.
• W1574906247 cites W2054186688 @default.
• W1574906247 cites W2055959245 @default.
• W1574906247 cites W2056877715 @default.
• W1574906247 cites W2062214650 @default.
• W1574906247 cites W2062553731 @default.
• W1574906247 cites W2067488379 @default.
• W1574906247 cites W2068193995 @default.
• W1574906247 cites W2072076347 @default.
• W1574906247 cites W2072951402 @default.
• W1574906247 cites W2076395978 @default.
• W1574906247 cites W2084983577 @default.
• W1574906247 cites W2088781778 @default.
• W1574906247 cites W2100015862 @default.
• W1574906247 cites W2100291696 @default.
• W1574906247 cites W2106815097 @default.
• W1574906247 cites W2128074212 @default.
• W1574906247 cites W2132276423 @default.
• W1574906247 cites W2132848064 @default.
• W1574906247 cites W2138521207 @default.
• W1574906247 cites W2141026681 @default.
• W1574906247 cites W2141813576 @default.
• W1574906247 cites W2151554609 @default.
• W1574906247 cites W2157006832 @default.
• W1574906247 cites W2160079991 @default.
• W1574906247 cites W2179508744 @default.
• W1574906247 cites W2398303081 @default.
• W1574906247 cites W2409441997 @default.
• W1574906247 cites W2414102206 @default.
• W1574906247 cites W2414612683 @default.
• W1574906247 cites W2419011273 @default.
• W1574906247 cites W2440208527 @default.
• W1574906247 cites W2571918371 @default.
• W1574906247 cites W4211004345 @default.
• W1574906247 cites W4243451814 @default.
• W1574906247 cites W4376596247 @default.
• W1574906247 doi "https://doi.org/10.1002/14651858.cd001245.pub2" @default.
• W1574906247 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8407182" @default.
• W1574906247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23990381" @default.
• W1574906247 hasPublicationYear "2013" @default.
• W1574906247 type Work @default.
• W1574906247 sameAs 1574906247 @default.
• W1574906247 citedByCount "110" @default.
• W1574906247 countsByYear W15749062472012 @default.
• W1574906247 countsByYear W15749062472013 @default.
• W1574906247 countsByYear W15749062472014 @default.
• W1574906247 countsByYear W15749062472015 @default.
• W1574906247 countsByYear W15749062472016 @default.
• W1574906247 countsByYear W15749062472017 @default.
• W1574906247 countsByYear W15749062472018 @default.
• W1574906247 countsByYear W15749062472019 @default.
• W1574906247 countsByYear W15749062472020 @default.
• W1574906247 countsByYear W15749062472021 @default.
• W1574906247 countsByYear W15749062472022 @default.
• W1574906247 countsByYear W15749062472023 @default.
• W1574906247 crossrefType "journal-article" @default.
• W1574906247 hasAuthorship W1574906247A5019984978 @default.
• W1574906247 hasAuthorship W1574906247A5023457875 @default.
• W1574906247 hasAuthorship W1574906247A5052591309 @default.
• W1574906247 hasAuthorship W1574906247A5057096729 @default.
• W1574906247 hasAuthorship W1574906247A5066554954 @default.
• W1574906247 hasAuthorship W1574906247A5077611966 @default.

• next